CoChat

OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

Open access

The DOI matches its Crossref record; 8 of the 9 references it cites were found in a registry or an index.

Abstract

BACKGROUND: In the OlympiAD study, olaparib was shown to improve progression-free survival compared with chemotherapy treatment of physician's choice (TPC) in patients with a germline BRCA1 and/or BRCA2 mutation (BRCAm) and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (mBC). We now report the planned final overall survival (OS) results, and describe the most common adverse events (AEs) to better understand olaparib tolerability in this population. PATIENTS AND METHODS: OlympiAD, a Phase III, randomized, controlled, open-label study (NCT02000622), enrolled patients with a germline BRCAm and HER2-negative mBC who had received ≤2 lines of chemotherapy for mBC. Patients were randomized to olaparib tablets (300 mg bid) or predeclared TPC (capecitabine, vinorelbine, or eribulin). OS and safety were secondary end points. RESULTS: A total of 205 patients were randomized to olaparib and 97 to TPC. At 64% data maturity, median OS was 19.3 months with olaparib versus 17.1 months with TPC (HR 0.90, 95% CI 0.66-1.23; P = 0.513); median follow-up was 25.3 and 26.3 months, respectively. HR for OS with olaparib versus TPC in prespecified subgroups were: prior chemotherapy for mBC [no (first-line setting): 0.51, 95% CI 0.29-0.90; yes (second/third-line): 1.13, 0.79-1.64]; receptor status (triple negative: 0.93, 0.62-1.43; hormone receptor positive: 0.86, 0.55-1.36); prior platinum (yes: 0.83, 0.49-1.45; no: 0.91, 0.64-1.33). Adverse events during olaparib treatment were generally low grade and manageable by supportive treatment or dose modification. There was a low rate of treatment discontinuation (4.9%), and the risk of developing anemia did not increase with extended olaparib exposure. CONCLUSIONS: While there was no statistically significant improvement in OS with olaparib compared to TPC, there was the possibility of meaningful OS benefit among patients who had not received chemotherapy for metastatic disease. Olaparib was generally well-tolerated, with no evidence of cumulative toxicity during extended exposure. Please see the article online for additional video content.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdz012

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Kaplan–Meier estimates for overall survival in the olaparib group and the chemotherapy TPC group for (A) the overall population and for subgroup analyses stratified by (B) prior chemotherapy for metastatic breast cancer, (C) hormone-receptor status, and (D) prior platinum. Nominal P values were calculated using a likelihood ratio test; OS stratification factors were prespecified but not alpha controlled. ER, estrogen receptor; L, line of therapy; mBC, metastatic breast cancer; NS, not significant; PgR, progesterone receptor; TNBC, triple-negative breast cancer.
Figure 1. Kaplan–Meier estimates for overall survival in the olaparib group and the chemotherapy TPC group for (A) the overall population and for subgroup analyses stratified by (B) prior chemotherapy for metastatic breast cancer, (C) hormone-receptor status, and (D) prior platinum. Nominal P values were calculated using a likelihood ratio test; OS stratification factors were prespecified but not alpha controlled. ER, estrogen receptor; L, line of therapy; mBC, metastatic breast cancer; NS, not significant; PgR, progesterone receptor; TNBC, triple-negative breast cancer.CC BY-NC · PubMed Central
Figure 2. Forest plots of final OS overall population and all subgroup analyses. BC, breast cancer; CI, confidence interval; ER, estrogen receptor; HR, hazard ratio; NC, not calculated; PgR, progesterone receptor; TPC, treatment of physician’s choice.
Figure 2. Forest plots of final OS overall population and all subgroup analyses. BC, breast cancer; CI, confidence interval; ER, estrogen receptor; HR, hazard ratio; NC, not calculated; PgR, progesterone receptor; TPC, treatment of physician’s choice.CC BY-NC · PubMed Central
Figure 3. Prevalence of all (solid lines) and grade ≥2 (dotted lines) (A) nausea* and (B) vomiting, and (C) all (solid lines) and grade ≥3 (dotted lines) anemia, during the OlympiAD study. *The probability of event in the TPC arm was 1.0 at 24 months.
Figure 3. Prevalence of all (solid lines) and grade ≥2 (dotted lines) (A) nausea* and (B) vomiting, and (C) all (solid lines) and grade ≥3 (dotted lines) anemia, during the OlympiAD study. *The probability of event in the TPC arm was 1.0 at 24 months.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 823

Metadata

Authors
Robson, M. E., Tung, N., Conte, P., Im, S.-A., Senkus, E., Xu, B., Masuda, N., Delaloge, S., Li, W., Armstrong, A., Wu, W., Goessl, C., Runswick, S., & Domchek, S. M.
Affiliations
  • Memorial Sloan Kettering Cancer Center (US)
  • Beth Israel Deaconess Medical Center (US)
  • University of Padua (IT)
  • Seoul National University (KR)
  • Gdańsk Medical University (PL)
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
  • Osaka National Hospital (JP)
  • Institut Gustave Roussy (FR)
  • First Hospital of Jilin University (CN)
  • The Christie Hospital (GB)
  • AstraZeneca (United States) (US)
  • AstraZeneca (United Kingdom) (GB)
  • University of Pennsylvania (US)
Corresponding author
  • Robson, M.E.
  • Runswick, S.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2019-04
Volume
30
Issue
4
Pages
558-566
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2913584903
Cited by
779
References
9
Citations by year
2026: 76 · 2025: 84 · 2024: 108 · 2023: 144 · 2022: 133 · 2021: 118 · 2020: 83 · 2019: 33
FWCI
38.45
Type
journal article
Language
en
Open access
Licence
Locations
  • Annals of Oncology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Seoul National University Open Repository (Seoul National University) (submittedVersion)
  • Padua Research Archive (University of Padova) (submittedVersion)
Funders
  • AstraZeneca
  • AstraZeneca and Merck & Co.
  • Inc.
  • NIH/NCI Cancer Center
  • Breast Cancer Research Foundation
  • Mudskipper Business Ltd
Topics
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Keywords
olaparib, HER2-negative metastatic breast cancer, germline BRCA1 mutation, germline BRCA2 mutation, PARP inhibitors, overall survival, tolerability, adverse events, capecitabine, vinorelbine, eribulin, platinum-based chemotherapy, triple-negative breast cancer, hormone receptor-positive breast cancer, Olympiad
MeSH terms
Poly(ADP-ribose) Polymerase Inhibitors, Progression-Free Survival, Administration, Oral, Adult, Aged, Anemia, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Female, Follow-Up Studies, Humans, Middle Aged, Phthalazines, Piperazines, Tablets, Germ-Line Mutation, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, BRCA1 Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. https://app.cochat.ai/papers/10.1093/annonc/mdz012
The paper
Robson, M. E., Tung, N., Conte, P., Im, S.-A., Senkus, E., Xu, B., Masuda, N., Delaloge, S., Li, W., Armstrong, A., Wu, W., Goessl, C., Runswick, S., & Domchek, S. M. (2019). OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology. https://doi.org/10.1093/annonc/mdz012

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.